Ingalls & Snyder LLC Heron Therapeutics, Inc. Transaction History
Ingalls & Snyder LLC
- $2.56 Billion
- Q3 2024
A detailed history of Ingalls & Snyder LLC transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Ingalls & Snyder LLC holds 13,415 shares of HRTX stock, worth $23,610. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,415
Previous 13,415
-0.0%
Holding current value
$23,610
Previous $47,000
42.55%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding HRTX
# of Institutions
180Shares Held
121MCall Options Held
80.4KPut Options Held
94.9K-
Rubric Capital Management LP New York, NY26.7MShares$47 Million1.48% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA8.85MShares$15.6 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.72MShares$15.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.33MShares$14.7 Million0.0% of portfolio
-
Velan Capital Investment Management LP Alpharetta, GA6.99MShares$12.3 Million28.8% of portfolio
About HERON THERAPEUTICS, INC.
- Ticker HRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 118,774,000
- Market Cap $209M
- Description
- Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...